Jeil Pharmaceutical Co., Ltd.

Quick facts

Marketed products

• Clopirin 1
• Clopirin 2 · Cardiovascular
  Clopirin 2 is an antiplatelet agent that inhibits platelet aggregation to reduce thrombotic events.
• "Metformin" and "Rosuvastatin" seperately

Phase 3 pipeline

• JLP-2002 A mg · Diabetes
  JLP-2002 A mg is a small molecule that targets the SGLT2 receptor.
• JT-003
  JT-003 is an investigational therapeutic agent in phase 3 development by Jeil Pharmaceutical, but its specific mechanism of action has not been publicly disclosed.
• Metformin + Rosuvastatin · Endocrinology / Cardiovascular
  This combination reduces blood glucose through metformin's inhibition of hepatic glucose production and increases insulin sensitivity, while rosuvastatin lowers cholesterol by inhibiting HMG-CoA reductase.
• placebo + Rosuvastatin · Cardiovascular
  Rosuvastatin inhibits HMG-CoA reductase, a key enzyme in the cholesterol biosynthesis pathway.

Phase 2 pipeline

• JPI-289 High-dose
• JPI-289 Low-dose
• OJP-2028

Phase 1 pipeline

• JC-013
• JLP-1207
• JLP-1310
• JLP-1310, Fasted followed by fed
• JLP-1310, Fed followed by fasted
• JLP-1401
• JLP-1901
• JLP-2002
• JLP-2004
• JLP-2004 qd
• JP-2266
• JPI-289
• Metformin and Rosuvastatin
• Tamsulosin and solifenacin
• Zeropix · Other

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Jeil Pharmaceutical Co., Ltd. portfolio CI brief
• Jeil Pharmaceutical Co., Ltd. pipeline updates RSS